Abacus Medicine postpones IPO

European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment". 

Read more

Make leukaemia therapy safer

A Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.

Read more

Nanobiotix spins out Curadigm

Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.

Read more

Double win for Novartis

It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.

Read more

Most expensive gene therapy globally approved

The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.

Read more

Healthy figures from Spain

At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.

Read more

Chiesi acquires ex-US Raxone marketing rights

Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.

Read more

AI improves protein manufacture

Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.

Read more